2Jefferics JL, Denfield SW, Price JF, et al. A prospective evaluation of nesiritide in the treatment of pediatrle heart failure. Pediatr Cardiol, 2006,27 (4) :402-407.
3Fonarow GC. B-type natfiuretie peptide : spectrum of application. Ne- siritide (recombinant BNP) for heart failure. Heart Fail Rev,2003,8(4) :321-325.
4Sabbatini ME. Natriuretic peptides as regulatory mediators of secreto- ry activity in the digestive system. Regulatory Peptides,2009,154 ( 1 - 3) :5-15.
5Pandey KN. Biology of natriuretic peptides and their receptors. Pep- tides,2005,26(6) :901-932.
6Hermann Schagger,Gebhard yon Jagow. Tricine-sodium dodecyl sul- fate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Analytical Biochemistry, 1987,166 (2) :368-379.
7Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharmaceutical Research ,2004, 21 ( 11 ) :2105-2110.
8Ondrej Lisy, Huntley BK, McCormick D J, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide:CD-NP. Journal of the American College of Cardiology ,2008,52( 1 ) :60-68.
9D'Souza SP, Davis M, Baxter GF. Autoerine and paraerine actions of natriuretic peptides in the heart. Pharmacology & Therapeutics, 2004,101 (2) :113-129.
